Ottawa: Health Canada has approved the first generic version of the blockbuster diabetes drug Ozempic, manufactured by India’s Dr. Reddy’s Laboratories, marking a significant development in the global market for affordable treatments.
First generic version enters Canadian market
The approval makes Dr Reddy’s the first company to introduce a generic version of Ozempic in Canada, a move expected to improve access and reduce costs for patients. Ozempic, developed by Novo Nordisk, is widely used for managing type 2 diabetes and has also gained popularity for weight management.
The entry of a generic alternative is likely to intensify competition and drive down prices, benefiting consumers.
Rising demand for affordable alternatives
Several pharmaceutical companies have been working on lower-cost versions of semaglutide, the active ingredient in Ozempic. The growing demand for these alternatives has already begun to impact pricing in some markets.
In March, India became the first major market to introduce generic versions of semaglutide after certain patent protections expired. This prompted Novo Nordisk to reduce prices of Ozempic and its obesity drug Wegovy in India.
More competition expected
Analysts say Canada could become a key testing ground for how generic versions compete with branded GLP-1 therapies. Evan Seigerman of BMO Capital Markets noted that investors will closely track developments in the Canadian market.
Meanwhile, Sandoz has announced plans to launch its own generic version of Ozempic in Canada by June, positioning itself among early entrants in the segment.
Health Canada has also confirmed that it is currently reviewing eight additional applications for generic semaglutide, with more approvals expected in the coming months.
Pressure on Novo Nordisk
Novo Nordisk is facing increasing competition not only from generics but also from rival GLP-1 drugs. Products such as Mounjaro and Zepbound, developed by Eli Lilly, are gaining market share and challenging the company’s dominance.
Despite this, analysts believe that strong intellectual property protections in the United States may limit the global impact of generic competition in the short term.
Potential cost benefits for patients
In Canada, generic medicines are typically priced 45 per cent to 90 per cent lower than their branded counterparts. The introduction of a generic Ozempic is therefore expected to significantly reduce treatment costs for patients, particularly those requiring long-term therapy.
Lower prices could also improve access to essential medications, especially for individuals without comprehensive insurance coverage.
Conclusion
The approval of the first generic version of Ozempic in Canada marks a major step towards affordable diabetes care. With more companies preparing to enter the market, competition is set to increase, potentially reshaping pricing dynamics and expanding access to treatment for patients worldwide.
Comments are closed.